Form 4: Nuvalent Chief Scientific Officer Exercises Options and Sells Shares Under Pre-Arranged Trading Plan

Nuvalent, Inc.'s Chief Scientific Officer, Henry E. Pelish, executed pre-planned transactions in June 2025, exercising stock options and subsequently selling a portion of the acquired shares under a Rule 10b5-1 trading plan.

Summary

• Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc. (NUVL), engaged in multiple transactions involving the company's Class A Common Stock on June 25, 2025, and June 27, 2025.
• On June 25, 2025, Mr. Pelish acquired a total of 8,630 shares (3,677 shares at $27.85 and 4,953 shares at $29.33) through the exercise of stock options.
• Concurrently on June 25, 2025, he disposed of 8,630 shares at a weighted average price of $79.87, with prices ranging from $79.80 to $79.92.
• On June 27, 2025, Mr. Pelish acquired an additional 2,170 shares (347 shares at $27.85 and 1,823 shares at $29.33) by exercising stock options.
• On the same day, June 27, 2025, he sold 2,170 shares at a weighted average price of $79.92, with prices ranging from $79.80 to $80.00.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 1, 2024.
• Following these transactions, Mr. Pelish's direct beneficial ownership of Class A Common Stock remained at 63,101 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there are insider sales, they are part of a pre-arranged 10b5-1 plan, which mitigates negative interpretations. The officer is realizing gains from vested options, which is a positive for the individual and reflects past stock appreciation.

Positives

• The transactions involved the exercise of stock options, indicating the realization of value from previously granted equity compensation.
• The sales were conducted at significantly higher prices ($79.87 and $79.92) than the option exercise prices ($27.85 and $29.33), demonstrating a substantial gain for the officer.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a systematic approach to managing equity holdings rather than a reaction to immediate negative news.

Negatives

• The disposition of shares by a Chief Scientific Officer could be interpreted by some investors as a reduction in insider exposure to the company's stock, although this is mitigated by the 10b5-1 plan.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report for a biotechnology company. Such transactions are common for executives managing their equity compensation and personal finances. The use of a Rule 10b5-1 plan is a standard practice to allow insiders to trade company stock without being accused of insider trading, as the plan is set up in advance when the insider is not in possession of material non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans for insider stock sales is a common and accepted practice across all industries, including biotechnology, to manage equity compensation and mitigate insider trading concerns.
• The exercise of stock options and subsequent sale of shares (often referred to as "sell-to-cover" or "cashless exercise" if the proceeds cover the exercise cost and taxes) is a standard method for executives to monetize their equity awards.
• The prices at which shares were sold ($79.87 and $79.92) are significantly higher than the exercise prices ($27.85 and $29.33), which is typical for successful equity compensation plans where the company's stock price has appreciated since the grant date.

Related Party Transactions

• The reported transactions are insider transactions, which are a form of related party transaction. Specifically, the Chief Scientific Officer, Henry E. Pelish, exercised stock options and sold shares of Nuvalent, Inc. stock.

Stakeholder Impact

• Shareholders: The sale of shares by an officer could be perceived as a slight negative, but the pre-arranged 10b5-1 plan mitigates concerns about a lack of confidence. The officer's continued significant direct ownership (63,101 shares) suggests ongoing alignment with shareholder interests.
• Employees: The exercise of stock options demonstrates the value of equity compensation plans, which can be a positive for employee morale and retention.

Key Dates

Recommendation

Keywords

Nuvalent Inc, NUVL, SEC Form 4, Insider Trading, Stock Options, Rule 10b5-1 Plan, Chief Scientific Officer, Equity Compensation, Share Sale, Beneficial Ownership